Toll-like receptor modulators: a patent review (2006 – 2010)
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: The immune response is mediated via two parallel immune components, innate and adaptive, whose effector functions are highly integrated and coordinated for the protection of the human body against invading pathogens and transformed cells. The discovery of pathogen recognition receptors (PRRs), most notably toll-like receptors (TLRs), in innate immunity has evoked increased interest in the therapeutic handling of the innate immune system. TLRs are germ line-encoded receptors that play a potent role in the recognition of a diverse variety of ligands ranging from hydrophilic nucleic acids to lipopolysaccharide (LPS) or peptidoglycan (PGN) structures in pathogens. AREAS COVERED: This review discusses recent updates (2006-2010) in completed, ongoing and planned clinical trials of TLR immunomodulator-based therapies for the treatment of infectious diseases, inflammatory disorders and cancer. EXPERT OPINION: Since the discovery of human TLRs, modulating immune responses using TLR agonists or antagonists for therapeutic purposes has provoked intense activity in the pharmaceutical industry. The ability of TLRs to initiate and propagate inflammation makes them attractive therapeutic targets. We are now at the stage of evaluating such molecules in human diseases. Additionally, there is also extensive literature available on TLRs in diseased states. These data provide a basis for the identification of novel immunomodulators (agonists and antagonists) for the therapeutic targeting of TLRs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8
Heil, F., Hemmi, H., Hochrein, H., Ampenberger, F., Kirschning, C., Akira, S., Lipford, G., Wagner, H., & Bauer, S. (2004) · Science · doi:10.1126/science.1093620 · Cited by 3,947 · cited 5×
“This has been a matter of debate regarding TLR targeting drugs due to the differences observed in expression and function of different TLRs, such as the key differences seen between the activation profiles of human and mouse TLR8 [119,120].”
BackgroundInfluentialToll-like receptors in systemic autoimmune disease
Marshak-Rothstein, A. (2006) · Nature Reviews Immunology · doi:10.1038/nri1957 · Cited by 1,116 · cited 1×
“Pathogen-encoded TLR ligands fall into three broad categories: lipids and lipopeptides (TLR2/1; TLR2/6 and TLR4), proteins (TLR5 and TLR11) and nucleic acids (TLR3, 7, 8 and 9) [2,11].”
BackgroundTherapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists
Kanzler, H., Barrat, F. J., Hessel, E. M., & Coffman, R. L. (2007) · Nature Medicine · doi:10.1038/nm1589 · Cited by 869 · cited 6×
“InDex Pharmaceuticals AB’s lead product DIMS 0150 has orphan drug designation in Europe and has completed its third clinical Phase II trial for the treatment of steroid-resistant/dependent ulcerative colitis [84].”
BackgroundInfluentialStructural Basis of Toll-Like Receptor 3 Signaling with Double-Stranded RNA
Liu, L., Botos, I., Wang, Y., Leonard, J. N., Shiloach, J., Segal, D. M., & Davies, D. R. (2008) · Science · doi:10.1126/science.1155406 · Cited by 733
Modulation of atherosclerosis in mice by Toll-like receptor 2
Mullick, A. E. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25482 · Cited by 549
Adding fuel to fire: microRNAs as a new class of mediators of inflammation
Sheedy, F. J., & O'Neill, L. A. J. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.100289 · Cited by 246 · cited 1×
“A key role for miRNAs in the regulation of genes involved in immune defense is currently being uncovered [112].”
BackgroundUngaro, R., Fukata, M., Hsu, D., Hernandez, Y., Breglio, K., Chen, A., Xu, R., Sotolongo, J., Espana, C., Zaias, J., et al. (2009) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.90496.2008 · Cited by 159 · cited 3×
“Cpn10 TLR4 CBio Ltd RA, MS, psoriasis Phase II [98] NI-0101 TLR4 NovImmune Acute and chronic inflammation Preclinical 1A6 TLR4 NovImmune Colitis Preclinical [102] AV411 TLR4 Avigen Pain management and withdrawal Phase II [101,125] IRS-954 (DV-1079) TLR7 and 9 Dynavax Technologies SLE, HIV Preclinical [106] IMO-3100 TL…”
BackgroundSelf-Adjuvanting Lipopeptide Vaccines
Moyle, P., & Toth, I. (2008) · Current Medicinal Chemistry · doi:10.2174/092986708783503249 · Cited by 155 · cited 1×
“Synthetic lipopeptide agonists for TLR2 exhibit strong adjuvant activity when either mixed with or directly conjugated to various antigens [32,33].”
Background
Cited by
Obesity, Inflammation, Toll-Like Receptor 4 and Fatty Acids
Rogero, M., & Calder, P. (2018) · Nutrients · doi:10.3390/nu10040432 · Cited by 706
SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates
Kyriakidis, N. C., López-Cortés, A., González, E. V., Grimaldos, A. B., & Prado, E. O. (2021) · npj Vaccines · doi:10.1038/s41541-021-00292-w · Cited by 698
The emerging role of Toll-like receptor 4 in myocardial inflammation
Yang, Y., Lv, J., Jiang, S., Ma, Z., Wang, D., Hu, W., Deng, C., Fan, C., Di, S., Sun, Y., et al. (2016) · Cell Death & Disease · doi:10.1038/cddis.2016.140 · Cited by 337
“signaling and induction of numerous pro-inflammatory pathways.(87) Apart from these, a viral protein-derived peptide”
BackgroundToll-Like Receptors, Associated Biological Roles, and Signaling Networks in Non-Mammals
Nie, L., Cai, S.-Y., Shao, J.-Z., & Chen, J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01523 · Cited by 329
Paredes Juárez, G. A., Spasojevic, M., Faas, M. M., & de Vos, P. (2014) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2014.00026 · Cited by 284
Metadata
- Authors
- Basith, S., Manavalan, B., Lee, G., Kim, S. G., & Choi, S.
- Venue
- Expert Opinion on Therapeutic Patents
- Publisher
- Informa UK Limited
- Published
- 2011-03-15
- Volume
- 21
- Issue
- 6
- Pages
- 927-944
- ISSN
- 1354-3776 (ISSN-L)
- 1744-7674
- OpenAlex
- W2102268163
- Cited by
- 103
- References
- 8
- FWCI
- 4.54
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Toll-like receptor modulators: a patent review (2006 – 2010). https://app.cochat.ai/papers/10.1517/13543776.2011.569494
- The paper
- Basith, S., Manavalan, B., Lee, G., Kim, S. G., & Choi, S. (2011). Toll-like receptor modulators: a patent review (2006 – 2010). Expert Opinion on Therapeutic Patents. https://doi.org/10.1517/13543776.2011.569494
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.